Drugmakers turn up marketing efforts in diabetes market
With a half-dozen new products lined up for approval within two years, the fight to win the growing $22 billion U.S. diabetes market is expected to intensify.
Home » Search
Search Results
199 results for 'Barclays'
- Sort By
-
Date
- Any Time
- Past Day
- Past Week
- Past Month
- Past Year
-
Custom Date Range
Articles
HHGregg strategy shift vaults stock to 52-week high
The Indianapolis-based appliance and electronics retailer’s stock hit a sort of milestone Tuesday, closing above $18 for the first time since early 2011.
Lilly’s new strategy built around head-to-head drug trials
Lilly has set up not one, not two, but five head-to-head trials of its experimental drug dulaglutide against other leading diabetes therapies. So far, dulaglutide’s record is four wins, no losses.
Regulators: JPMorgan owes $410M for price manipulation
The Federal Energy Regulatory Commission said the bank used improper bidding strategies to squeeze excessive payments from two power grid operators, including the Midcontinent Independent System Operator, which is based in Carmel.
Skarbeck: Weak results take glow off ‘risk parity’ strategy
The popular institutional investment strategy called “risk parity” has produced dreadful investment results this year.
High-profile developer chases Indy debut
Cleveland-based Forest City Enterprises Inc., developer of the 76-story New York by Gehry in New York City, is teaming with Keystone Group in its bid to redevelop a prime piece of downtown real estate where Market Square Arena once stood.
Stonegate raises $115M to fund jumbo mortgage expansion
The fast-growing Indianapolis-based firm will use the funds to fuel originations of loans not intended for government-backed programs, as well as to build its portfolio of servicing contracts, CEO Jim Cutillo said.
Unemployment aid applications fall to five-year low
Much of the job growth has come from fewer layoffs. Overall hiring remains far below pre-recession levels.
Obamacare exchanges could zap WellPoint profits
According to one estimate, the Indianapolis-based health insurer will shed $400 million in pre-tax profits by 2017.
Lilly on the rise as investors run back to pharma stocks
Investors are gaining confidence in the ability of major drugmakers, including Eli Lilly and Co., to improve their pipelines of new products. The big pharma firms begin to report first-quarter earnings this week.
Company news
Johnson & Johnson won approval for the first in a new family of diabetes drugs, giving the New Jersey-based drugmaker an edge over Eli Lilly and Co. and other rivals developing similar medicines. On Friday, the U.S. Food and Drug Administration cleared the drug, known as canagliflozin, to treat adults with Type 2 diabetes. It will be sold under the brand name Invokana and may generate as much as $800 million in annual sales, Tony Butler, an analyst at Barclays Plc in New York, told Bloomberg News. The drug is part of a class called SGLT2 inhibitors, which expel sugar in the urine after the kidneys filter it out of the blood. Similar drugs are being developed by Indianapolis-based Lilly, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co. and AstraZeneca plc.
Medical claims will rise more than 67 percent—the third-highest rate in the nation—for Indiana residents buying individual health insurance policies under President Barack Obama's health care overhaul, according to a study by the Society of Actuaries. The projected increase is partly due to sicker people joining the insurance pool. The study says most states will see increases, and assumes every state will expand its Medicaid program, but that's uncertain in Indiana. The Obama administration says the study ignores subsidies to help with premiums. Middle-class households can buy subsidized insurance in new marketplaces Oct. 1. The report doesn't cover employer plans.
Dow AgroSciences LLC will formally open a 175,000-square-foot building on April 10, which will be home to 200 researchers working on plant biotechnology. Dow AgroSciences first announced the $340 million expansion in March 2010, saying it would lead to an additional 577 high-paying jobs over the following five years. The company, which is a subsidiary of Michigan-based Dow Chemical Co., said most of the positions would pay $65,000 to $95,000 annually. Dow AgroSciences had sales last year of $6.4 billion, and produced earnings before taxes, interest, depreciation and amortization of $977 million.
J&J wins OK for first in new class of diabetes drugs
Johnson & Johnson, the world’s largest seller of health-care products, won approval for the first in a new family of diabetes drugs, giving them the edge against rivals including Eli Lilly and Co. that are developing similar medicines.
WellPoint shares tumble on surprising CEO hire
The Indianapolis-based health insurer saw its stock tumble as much as 4.8 percent Wednesday morning after it unexpectedly named career hospital executive Joe Swedish to be its next CEO.
Lilly aims to submit five new drugs for approval
With Eli Lilly and Co. set to see patents expire on its best-selling drug at year’s end, it is in the company’s interest to say its pipeline is about to produce new drugs. But the Indianapolis drugmaker may be in a position to submit five new drugs for regulatory approval this year.
HHGregg ratchets back, but analysts still uneasy
HHGregg now has 228 stores in 20 states. So it has grown a great deal. But the “exceptional store economics” it used to promote are gone, thanks largely to a breathtaking collapse in sales of flat-screen televisions.
Analysts: ITT’s woes are likely to worsen
Investors have dumped the already-depressed shares of ITT Educational Services Inc. after the operator of for-profit colleges shelled out $46 million for bad private student loans it had backed to help students pay the portion of its pricey tuition that federal loans won’t cover. With fewer ITT graduates able to find jobs, the default rates on these loans has spiked.
Surprise on-field success driving Colts’ club-seat sales
What had looked like a bleak scenario for renewals took a positive turn thanks to wins racked up by the team and rookie quarterback Andrew Luck.
State’s largest private company on verge of IPO
Berry Plastics Group Inc., the largest private company in Indiana, may set terms for its initial public offering as soon as this week, said two people with knowledge of the matter.
Investor still pushing for Simon to buy rival despite opposition
Brookfield Asset Management Inc. is keeping a tight grip on its stake in General Growth Properties Inc. in a bet the second-largest U.S. mall owner is better off as an independent company that will jump in value.
Simon exec: There’s ‘no interest’ in buying General Growth
A Simon Property Group Inc. executive said that the largest U.S. mall owner isn’t trying to acquire competitor General Growth Properties Inc., which announced Monday that it won’t put itself up for sale.